A Meta-Analysis of the Effects of Homocysteine-Lowering Therapy on Chronic Kidney Disease
Hormone and Metabolic Research · 01.01.2026 · 58 (01) · 13-22
DOI: 10.1055/a-2780-5656 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.01.2026. Verfasst von Hua Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition, Qilu Hospital of Shandong University Qingdao, Qingdao, China. Hauptthemen laut MEDLINE: Folic Acid, Homocysteine, Hyperhomocysteinemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Hyperhomocysteinemia is common in chronic kidney disease; however, whether homocysteine-lowering therapy slows chronic kidney disease progression remains uncertain. Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guideline, we systematically searched PubMed and Web of Science (inception to January 2025) for randomized controlled trials evaluating folic acid alone or combined with vitamin B versus placebo/usual care/low-dose regimens in populations across the chronic kidney disease spectrum. The primary end point was composite kidney outcomes (all-cause mortality, cardiovascular events, and kidney disease progression). Relative risks with 95% confidence intervals were pooled using fixed- or random-effect models according to heterogeneity. Nine trials comprising 23,638 participants met inclusion criteria. Overall heterogeneity for the primary outcome was low (I²=27%), and homocysteine-lowering therapy was associated with a marginal reduction in composite kidney outcomes (relative risk=0.96 and 95% confidence interval=0.92–1.00; p = 0.04). Subgroup analyses suggested a greater benefit in participants with normal to moderate chronic kidney disease (relative risk=0.89 and 95% confidence interval=0.81–0.97; p=0.008) and in non-White populations (relative risk=0.89 and 95% confidence interval=0.81–0.97; p=0.008). No significant effects were observed for cardiovascular events (relative risk=0.94 and 95% confidence interval=0.84–1.06) or all-cause mortality (relative risk=0.99 and 95% confidence interval 0.87–1.11). In conclusion, homocysteine-lowering therapy yields, at most, a small reduction in composite kidney outcomes with limited clinical significance and provides no detectable benefits for cardiovascular events or mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Nutrition, Qilu Hospital of Shandong University Qingdao, Qingdao, China.
- Department of Clinical Psychology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zitieren
APA
Lin, H., Liu, Y., Geng, S., Sun, Y., Li, X., Li, B., & Liu, Y. (2026). A Meta-Analysis of the Effects of Homocysteine-Lowering Therapy on Chronic Kidney Disease. Hormone and Metabolic Research, 58(01), 13-22. https://doi.org/10.1055/a-2780-5656
Vancouver
Lin H, Liu Y, Geng S, Sun Y, Li X, Li B, et al. A Meta-Analysis of the Effects of Homocysteine-Lowering Therapy on Chronic Kidney Disease. Hormone and Metabolic Research. 2026;58(01):13-22. doi:10.1055/a-2780-5656
BibTeX
@article{Lin2026,
author = {Lin, Hua and Liu, Yang and Geng, Shuo and Sun, Yanpei and Li, Xuemei and Li, Bohan and Liu, Yuantao},
title = {A Meta-Analysis of the Effects of Homocysteine-Lowering Therapy on Chronic Kidney Disease},
journal = {Hormone and Metabolic Research},
year = {2026},
volume = {58},
number = {01},
pages = {13--22},
doi = {10.1055/a-2780-5656}
}
EUVIMED